Alpine Immune Sciences Inc (NASDAQ:ALPN) presented the first clinical data of povetacicept in autoimmune glomerulonephritis during a late-breaking session at the American Society of Nephrology (ASN) Kidney Week.
In IgAN, treatment with low-dose povetacicept, 80 mg SC every four weeks, was associated with clinically meaningful improvements in proteinuria, with a 53.5% reduction from baseline in UPCR (n=5) at 24 weeks.
In addition, at 24 weeks, 4/5 (80%) had achieved remission, as defined as UPCR < 0.5 g/g and ≥50% reduction in UPCR from baseline with stable renal function (≤ 25% reduction in eGFR from baseline).
In IgAN, treatment with low-dose povetacicept was also associated with a >60% reduction in the key disease-related biomarker galactose-deficient IgA1 (Gd-IgA1), as well as stable renal function as assessed by estimated glomerular filtration rate (eGFR) (+7.1% from baseline at 24 weeks; n=5).
The first participant with primary membranous nephropathy (pMN), also treated with povetacicept 80 mg SC every four weeks, achieved an immunological remission, defined as a reduction in the highly disease-relevant biomarker anti-PLA2R1 to an undetectable level, from a baseline of 209 to < 2 RU/mL by 22 weeks.
Povetacicept has been well tolerated, with no reported administration-associated reactions, no instances of IgG < 3 g/L, and no severe infections.
A higher dose of povetacicept, 240 mg SC every four weeks, continued to enroll, with initial data expected in 1H 2024.
Price Action: ALPN shares are up 39.35% at $14.66 on the last check Thursday.
Read Next: SolarWinds Shares Jump Following Q3 Results and Optimistic Full-Year Forecasts
